Development and Validation of a UHPLC–MS/MS Method for the Quantification of a Novel PYGB Inhibitor in Plasma: Application to Pharmacokinetic Studies

In previous studies, we reported compound 1 (5-chloro-N-(4-oxo-2,2-dipropyl-3,4-dihydro-2H-benzo[e][1,3]oxazin-6-yl)-1H-indole-2-carboxamide) as a novel PYGB inhibitor, and found that it had better anti-ischemic brain injury activity. In this study, we established and validated a novel UHPLC–MS/MS m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Sumei, Li, Shuai, Yan, Zhiwei, Wang, Youde, Zhang, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574475/
https://www.ncbi.nlm.nih.gov/pubmed/37836837
http://dx.doi.org/10.3390/molecules28196995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574475/
https://www.ncbi.nlm.nih.gov/pubmed/37836837
http://dx.doi.org/10.3390/molecules28196995

Ejemplares similares